Johnson & Johnson (NYSE:JNJ) CAO Robert J. Decker Sells 16,928 Shares

Johnson & Johnson (NYSE:JNJGet Rating) CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Johnson & Johnson Trading Up 0.1 %

NYSE JNJ opened at $177.01 on Thursday. The company has a fifty day simple moving average of $168.35 and a two-hundred day simple moving average of $171.28. The stock has a market cap of $462.79 billion, a P/E ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the company posted $2.60 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. Johnson & Johnson’s payout ratio is currently 62.95%.

Johnson & Johnson announced that its board has authorized a share buyback program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Atlantic Securities lowered their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Citigroup decreased their target price on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Raymond James decreased their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Finally, Barclays initiated coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in JNJ. RE Dickinson Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after acquiring an additional 98 shares during the period. Advanced Research Investment Solutions LLC grew its position in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after buying an additional 120 shares during the period. Morton Brown Family Wealth LLC grew its position in Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after buying an additional 78 shares during the period. Professional Financial Advisors LLC grew its position in Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after buying an additional 68 shares during the period. Finally, Goodman Advisory Group LLC acquired a new stake in Johnson & Johnson during the second quarter valued at $39,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.